Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STOK 
Stoke Therapeutics Inc (STOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: STOK (5-star) is a SELL. SELL since 5 days. Simulated Profits (159.63%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $29.78
1 Year Target Price $29.78
| 7 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.87% | Avg. Invested days 41 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.28B USD | Price to earnings Ratio 32.9 | 1Y Target Price 29.78 |
Price to earnings Ratio 32.9 | 1Y Target Price 29.78 | ||
Volume (30-day avg) 10 | Beta 1.14 | 52 Weeks Range 5.35 - 38.69 | Updated Date 11/11/2025 |
52 Weeks Range 5.35 - 38.69 | Updated Date 11/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.5805 | Actual -0.65 |
Profitability
Profit Margin 19.73% | Operating Margin (TTM) -405.3% |
Management Effectiveness
Return on Assets (TTM) 5.2% | Return on Equity (TTM) 15.02% |
Valuation
Trailing PE 32.9 | Forward PE 204.08 | Enterprise Value 1060296049 | Price to Sales(TTM) 6.21 |
Enterprise Value 1060296049 | Price to Sales(TTM) 6.21 | ||
Enterprise Value to Revenue 5.16 | Enterprise Value to EBITDA 36.45 | Shares Outstanding 57117150 | Shares Floating 40560031 |
Shares Outstanding 57117150 | Shares Floating 40560031 | ||
Percent Insiders 4.19 | Percent Institutions 115.14 |
Upturn AI SWOT
Stoke Therapeutics Inc
Company Overview
History and Background
Stoke Therapeutics Inc. was founded in 2014 and is focused on developing antisense oligonucleotide (ASO) medicines to treat severe genetic diseases by upregulating protein expression. They leverage their TANGO (Targeted Augmentation of Nuclear Gene Output) platform.
Core Business Areas
- RNA-Based Therapeutics: Development of RNA-based therapeutics for genetic diseases with insufficient protein production, specifically focused on ASOs.
Leadership and Structure
Edward Kaye, M.D. serves as the Chief Executive Officer. The company has a typical biotech organizational structure with research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- STK-001 (Dravet Syndrome): STK-001 is an antisense oligonucleotide being developed for the treatment of Dravet syndrome. It aims to increase levels of the protein encoded by the SCN1A gene. It is in clinical trials. Competitors: Zogenix (Fintepla), Biocodex (Diazepam Buccal Film).
Market Dynamics
Industry Overview
The RNA therapeutics industry is experiencing rapid growth, driven by technological advancements and increasing success in treating genetic diseases. There is high competition and high regulatory scrutiny.
Positioning
Stoke is positioned as a leader in developing ASO therapies for diseases caused by haploinsufficiency, focusing on upregulation rather than knockdown. Their TANGO platform gives them a competitive edge.
Total Addressable Market (TAM)
The TAM for Dravet syndrome is estimated to be in the hundreds of millions to billions of dollars. Stoke's position within this TAM depends on the success of STK-001 and its ability to capture market share.
Upturn SWOT Analysis
Strengths
- Novel TANGO platform
- Strong scientific team
- First-mover advantage in upregulating gene expression
- Focus on severe unmet needs
Weaknesses
- Clinical trial risk
- Reliance on a single technology platform
- High cash burn rate
- Regulatory hurdles
Opportunities
- Expansion to other genetic diseases
- Partnerships with larger pharmaceutical companies
- Advancements in RNA delivery technologies
- Positive clinical trial data
Threats
- Competition from other RNA therapeutics companies
- Failure of clinical trials
- Regulatory setbacks
- Patent disputes
Competitors and Market Share
Key Competitors
- IONS
- CRSP
- PTCT
Competitive Landscape
Stoke competes with other companies developing RNA-based therapies. Stoke's TANGO platform and focus on upregulation differentiate them. Their clinical trial success will be key for establishing a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the progress of STK-001 clinical trials and securing funding.
Future Projections: Future projections depend on clinical trial outcomes and potential FDA approval of STK-001 and are unavailable without up-to-date APIs.
Recent Initiatives: Recent initiatives include advancing STK-001 through clinical trials and expanding their pipeline of ASO therapeutics.
Summary
Stoke Therapeutics is a clinical-stage biotech company with a novel platform targeting genetic diseases. Success hinges on the progress of STK-001. They need to secure funding and demonstrate clinical efficacy. Competition in RNA therapeutics is fierce; positive data is essential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Forward-looking statements are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stoke Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2019-06-19 | CEO & Director Mr. Ian F. Smith A.C.A., C.P.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | |
Full time employees 128 | |||
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.